New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More

Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?

By Zacks Equity Research | February 05, 2026, 9:40 AM

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One company to watch right now is Amneal Pharmaceuticals (AMRX). AMRX is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. AMRX has a P/S ratio of 1.55. This compares to its industry's average P/S of 4.46.

Finally, we should also recognize that AMRX has a P/CF ratio of 10.89. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. AMRX's P/CF compares to its industry's average P/CF of 14.01. Within the past 12 months, AMRX's P/CF has been as high as 61.60 and as low as 8.57, with a median of 16.33.

Value investors will likely look at more than just these metrics, but the above data helps show that Amneal Pharmaceuticals is likely undervalued currently. And when considering the strength of its earnings outlook, AMRX sticks out as one of the market's strongest value stocks.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Latest News